Conflicts of Interest The authors have declared no conflicts of interest.
Prevention of antibody-mediated kidney transplant rejection
Article first published online: 15 MAY 2012
© 2012 The Authors. Transplant International © 2012 European Society for Organ Transplantation
Special Issue: Special Focus - Antibody-Mediated Rejection
Volume 25, Issue 6, pages 633–645, June 2012
How to Cite
Morath, C., Opelz, G., Zeier, M. and Süsal, C. (2012), Prevention of antibody-mediated kidney transplant rejection. Transplant International, 25: 633–645. doi: 10.1111/j.1432-2277.2012.01490.x
- Issue published online: 15 MAY 2012
- Article first published online: 15 MAY 2012
- Received: 21 November 2011 Revision requested: 25 January 2012 Accepted: 10 April 2012
- antibody-mediated rejection;
- HLA antibodies;
- kidney transplantation;
There is increasing evidence that antibody-mediated rejection is the major cause of late kidney graft failure. Prevention of antibody-mediated allograft damage has therefore become an important issue in kidney transplantation. Such prevention starts already before transplantation with the avoidance of sensitizing events. When a patient is already sensitized, precise characterization of alloantibodies and exact HLA typing of the donor at the time of transplantation are mandatory. To ensure timely and successful transplantation of highly sensitized patients, desensitization, and inclusion in special programs such as the Eurotransplant Acceptable Mismatch Program should be considered. After transplantation, close monitoring of kidney function, testing for the de novo development or changing characteristics of alloantibodies, and attention to non-adherence to immunosuppression is obligatory. In the current overview, we discuss the currently available measures for the prevention of antibody-mediated kidney graft rejection.